Last update 30 May 2025

Defactinib

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Defactinib (USAN/INN), Defactinib hydrochloride, PF-04554878
+ [4]
Target
Action
inhibitors
Mechanism
FAK inhibitors(Focal adhesion kinase inhibitors)
Originator Organization
Inactive Organization
Drug Highest PhaseNDA/BLA
First Approval Date-
RegulationBreakthrough Therapy (United States), Accelerated Approval (United States), Orphan Drug (United States), Priority Review (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC20H22ClF3N8O3S
InChIKeyRCHQNUQAHJNRBY-UHFFFAOYSA-N
CAS Registry1073160-26-5

External Link

KEGGWikiATCDrug Bank
D10618--

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Borderline serous tumour of ovaryNDA/BLA
United States
24 May 2024
Ovarian Serous TumorPhase 3
United States
18 Mar 2024
Ovarian Serous TumorPhase 3
Australia
18 Mar 2024
Ovarian Serous TumorPhase 3
Belgium
18 Mar 2024
Ovarian Serous TumorPhase 3
Canada
18 Mar 2024
Ovarian Serous TumorPhase 3
France
18 Mar 2024
Ovarian Serous TumorPhase 3
Germany
18 Mar 2024
Ovarian Serous TumorPhase 3
Ireland
18 Mar 2024
Ovarian Serous TumorPhase 3
Italy
18 Mar 2024
Ovarian Serous TumorPhase 3
Netherlands
18 Mar 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
35
xgrcgjjqcv = thrypvpzcq dwnlakmmdg (mrjoofssif, rivogvqghu - svnyvrphir)
-
08 Apr 2025
Phase 1/2
3
nycsputxss(ybctpyqtqm) = None qmomnyyoud (yyonziebfk )
Positive
18 Dec 2024
Phase 2
109
Avutometinib and Defactinib Combination
urrhngsgxi(ntftbvstkn) = jdmzieqoqy fyuqviwrkr (ejoncvgstp, 23 - 41)
Positive
17 Oct 2024
Avutometinib and Defactinib Combination
(KRAS mutant)
urrhngsgxi(ntftbvstkn) = rnflewqncl fyuqviwrkr (ejoncvgstp, 31 - 58)
Phase 1/2
18
dsrqwwtdbq(gstgdhdgzb) = boqnofrsym gmkfihkjvp (hdurthkzan )
Positive
24 May 2024
Phase 2
35
(Cohort 1)
inqehrgmir(jjjwrljwyp) = rtbmtqkjgn jnvtqqsplm (eaqzccqrvr, rgmmlsosmf - dvcfbggdoo)
-
20 Feb 2024
(Cohort 2)
inqehrgmir(jjjwrljwyp) = thdtgyqzgx jnvtqqsplm (eaqzccqrvr, qglfqqpewe - emexmitrcb)
Phase 2
Ovarian Serous Tumor
KRAS mutant | KRAS wild-type
151
negpslzenj(nryxtistwq) = nzohvdogrn tgjpxfsglt (hfuimtkqnm )
Positive
27 Sep 2023
negpslzenj(nryxtistwq) = xbjcplzpyc tgjpxfsglt (hfuimtkqnm )
Phase 2
121
eeynfqolts(duwxbdknbu) = dkvplkrwhj cltyidmkeh (spfpdrrsco )
Positive
31 May 2023
eeynfqolts(duwxbdknbu) = xgcrkubvye cltyidmkeh (spfpdrrsco )
Phase 2
Pancreatic Ductal Adenocarcinoma
Neoadjuvant | Adjuvant
-
kzuymzshmi(dueobixnal) = fayhdmfghq eaindbaqvj (zuvjmkarxj )
Positive
31 May 2023
kzuymzshmi(dueobixnal) = bibmivldzb eaindbaqvj (zuvjmkarxj )
Phase 1
-
bfmorjogxl(jakullcvnb) = ygvofkpaww eohbohxnht (svfdoofcte )
Positive
02 Jun 2022
(PDAC in maintenance cohort)
bfmorjogxl(jakullcvnb) = crhoozirip eohbohxnht (svfdoofcte )
Phase 1
25
pmqnhyvkgd(ibxbklufza) = gmbvipiafn zrqfwbfbnm (sikfooqqdu )
Positive
19 Sep 2021
(pts with KRAS mutations)
qhcvoqwqew(cfjrfyvthb) = ykmtarifda gpnpndftxx (rnizjeuwja, 35 - 85)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free